EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Practical recommendations for the treatment of chorea associated with Huntington's disease: An expert consensus

Erin Furr Stimming, Jee Bang iD, Amy Brown iD, Bisena Bulica, Samuel Frank iD, David Houghton, Nikolaus R McFarland, Tiago A Mestre, Stephen Aradi, Victor Sung iD, Daniel Claassen

Journal of Huntington's Disease · 2026-11 · 15 (4) · 563-573

DOI: 10.1177/18796397261468482 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Huntington's Disease, online erschienen am 14.07.2026. Verfasst von Erin Furr Stimming und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Huntington Disease, Chorea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Neurocrine Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington's disease (HD) is a rare, autosomal dominant neurodegenerative disorder caused by a pathogenic CAG expansion in the huntingtin gene, classically characterized by a triad of cognitive, psychiatric, and motor symptoms. Involuntary movements known as chorea are the most notable feature of HD. Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice. Barriers include anosognosia, a complex treatment landscape, limited evidence-based guidelines, and variable access to care. In February 2025, 11 North American HD specialists and members of the Huntington Study Group (HSG) Motor Treatment Task Force, who collectively care for ∼1500 people with HD (PwHD) convened to discuss current practices and challenges in the pharmacologic treatment of chorea. Insights were supplemented by responses to a long-form questionnaire distributed via email. Attendees and respondents described practical approaches to assessing chorea, engaging care partners, and setting goal-oriented treatment plans. This review draws on collective experience to highlight practical, real-world strategies for the evaluation and treatment of HD chorea. The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics. Individualized titration, regular patient and care partner feedback, and functional, rather than purely motor-based, assessments are key to optimizing therapy. By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseChoreaHumansConsensusTetrabenazine

Stichwörter der Autor:innen

Huntington's diseaseVMAT2 inhibitorantipsychoticchoreachorea treatment

Substanzen

Tetrabenazine

Autor:innen und Institutionen

  • Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Departments of Neurology and Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Neurology, Henry Ford Hospital, Detroit, MI, USA.
  • Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Department of Neurology, Ochsner Health, New Orleans, Louisiana, USA.

ORCID-Profile: Jee Bang, Amy Brown, Samuel Frank, Victor Sung

Förderung

  • Neurocrine Biosciences

Zitieren

APA

Furr Stimming, E., Bang, J., Brown, A., Bulica, B., Frank, S., Houghton, D., McFarland, N. R., Mestre, T. A., Aradi, S., Sung, V., & Claassen, D. (2026). Practical recommendations for the treatment of chorea associated with Huntington's disease: An expert consensus. Journal of Huntington's Disease, 15(4), 563-573. https://doi.org/10.1177/18796397261468482

Vancouver

Furr Stimming E, Bang J, Brown A, Bulica B, Frank S, Houghton D, et al. Practical recommendations for the treatment of chorea associated with Huntington's disease: An expert consensus. Journal of Huntington's Disease. 2026;15(4):563-573. doi:10.1177/18796397261468482

BibTeX
@article{FurrStimming2026,
  author = {Furr Stimming, Erin and Bang, Jee and Brown, Amy and Bulica, Bisena and Frank, Samuel and Houghton, David and McFarland, Nikolaus R and Mestre, Tiago A and Aradi, Stephen and Sung, Victor and Claassen, Daniel},
  title = {Practical recommendations for the treatment of chorea associated with Huntington's disease: An expert consensus},
  journal = {Journal of Huntington's Disease},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {563--573},
  doi = {10.1177/18796397261468482}
}
Kostenlos starten →